Last reviewed · How we verify
KB707
At a glance
| Generic name | KB707 |
|---|---|
| Sponsor | Krystal Biotech, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (PHASE1, PHASE2)
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KB707 CI brief — competitive landscape report
- KB707 updates RSS · CI watch RSS
- Krystal Biotech, Inc. portfolio CI